BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Which Instax Camera Would it be a good idea for you to Purchase? - 2The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- 3Ways to track down the Right Criminal Legal counselor
- 4Solid Propensities: Little Changes for a Superior Life
- 5Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- Manual for Notorious Fragrances: Immortal Aromas
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- Change Your Skincare: 10 Inventive Magnificence Gadgets
- Instructions to Explore the Universe of Vehicle Leases
- Nordic people know how to beat the winter blues. Here's how to find light in the darkest months
- Must-See Public Parks from Around the Globe
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- Most loved Fish Dish: What's Your Sea Pleasure?
- The hunt for dark matter: a trivia quiz
